Roche Acquires Stratos Genomics to Advance Development of DNA-Based Sequencing for Diagnostic Use
By LabMedica International staff writers Posted on 23 May 2020 |
Image: SBX™ Genome Sequencing Technology (Photo courtesy of Stratos Genomics)
Roche (Basel, Switzerland) has acquired Stratos Genomics (Seattle, WA, USA), an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer.
The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX). The Roche nanopore sequencer, once developed, will utilize a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing. The addition of the SBX chemistry, once fully developed, is expected to provide the healthcare community an affordable, fast and flexible result, for multiple targeted clinical applications as well as whole exome and whole genome sequencing.
“Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients,” said Thomas Schinecker, CEO Roche Diagnostics. “We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche.”
“We are thrilled to join the Roche family, which will allow us to combine our unique Sequencing by Expansion chemistry with the Roche nanopore sequencer,” said Mark Kokoris, President & CEO at Stratos Genomics. “With our combined expertise and complementary technologies, we are well-positioned to open the path to deliver scalable, high-performance sequencing to clinicians and researchers.”
The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX). The Roche nanopore sequencer, once developed, will utilize a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing. The addition of the SBX chemistry, once fully developed, is expected to provide the healthcare community an affordable, fast and flexible result, for multiple targeted clinical applications as well as whole exome and whole genome sequencing.
“Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients,” said Thomas Schinecker, CEO Roche Diagnostics. “We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche.”
“We are thrilled to join the Roche family, which will allow us to combine our unique Sequencing by Expansion chemistry with the Roche nanopore sequencer,” said Mark Kokoris, President & CEO at Stratos Genomics. “With our combined expertise and complementary technologies, we are well-positioned to open the path to deliver scalable, high-performance sequencing to clinicians and researchers.”
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants